The pause affects Sotrovimab from GlaxoSmithKline. The federal government is sharply pulling back on one of the monoclonal antibody treatments authorized for COVID-19, pausing its use across eight ...
The expanded authorization was based on data from the phase 2/3 BLAZE-1 trial. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab plus ...
New data has shown the benefits of adding a CD38 monoclonal antibody onto the standard 3-drug regimen for patients with newly diagnosed, transplant-eligible multiple myeloma (MM). For patients with ...
U.S. Navy Petty Officer 3rd Class Andre May, a Sailor with Expeditionary Medical Facility-M and a native of Mount Vernon, N.Y., checks a patient’s blood pressure at Baton Rouge General Mid City campus ...
—These drugs should be the mainstay of HER2-positive breast cancer treatment, says Melissa McShane, MD, assistant professor and associate program director of the hematology/oncology fellowship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results